Curaleaf Executive Chairman Boris Jordan Says Both Presidential Candidate Have Come Out And Support Some Form Of Legislation Of Cannabis; Unlikely To Be Trump's Number One Priority; Will Matter Who DOJ Head Is Under Trump Administration; Trump, In My Opinion, Will Not Overrule Them; If He Puts Someone Moderate Or Friendly It Could Be Game Changer
Portfolio Pulse from Benzinga Newsdesk
Curaleaf's Executive Chairman, Boris Jordan, stated that both presidential candidates support some form of cannabis legislation. However, it is unlikely to be Trump's top priority. The impact will depend on the DOJ head under Trump, as a moderate or friendly appointment could be a game changer.
October 08, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Curaleaf's Executive Chairman, Boris Jordan, notes bipartisan support for cannabis legislation, but emphasizes the importance of the DOJ head under a potential Trump administration. A moderate or friendly DOJ head could significantly impact Curaleaf's business environment.
Curaleaf, being a major player in the cannabis industry, stands to benefit from any positive legislative changes. The mention of bipartisan support is positive, but the uncertainty around the DOJ head under Trump adds a variable. A favorable DOJ head could lead to a more supportive regulatory environment, benefiting Curaleaf.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
The potential for cannabis legislation supported by both presidential candidates could positively impact the AdvisorShares Pure US Cannabis ETF (MSOS), which invests in US cannabis companies. The DOJ head under Trump could influence the regulatory landscape.
MSOS, an ETF focused on US cannabis companies, could benefit from favorable legislation. The bipartisan support is a positive signal, but the regulatory environment under a Trump administration remains uncertain, hinging on the DOJ head's stance.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70